Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2017.07.032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19.
Arch Pharm Res
January 2025
College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, Republic of Korea.
Article Synopsis
- Gliclazide is a medication for type 2 diabetes, primarily metabolized by genetic variations in the CYP2C9 and CYP2C19 enzymes.
- A physiologically based pharmacokinetic (PBPK) model was developed to analyze how these genetic differences affect gliclazide's effects in patients.
- The model accurately predicted drug concentration levels in the bloodstream, meeting standard evaluation criteria and potentially paving the way for personalized treatment plans based on genetic profiles.
Hypothesized pharmacogenomic and medication influences on tetrahydrocannabinol and cannabidiol metabolism in a cohort of unselected oral cannabis users.
J Cannabis Res
January 2025
Division of General Internal Medicine, Mayo Clinic College of Medicine and Science, 200 First St SW, Rochester, MN, 55905, USA.
Background: Differences in cannabinoid metabolism and patient responses can arise even with equivalent doses and formulations. Genetic polymorphisms in genes responsible for cannabinoid metabolism and medications that alter CYP450 pathways responsible for metabolism of cannabinoids may account for some of this variability.
Materials And Methods: A retrospective chart review was conducted on a cohort of unselected patients who had previously completed pharmacogenomic testing and reported oral cannabis use, as defined as "oral" or "by mouth" route of administration.
Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024).
Ann Acad Med Singap
December 2024
Institute of Mental Health, Singapore.
Introduction: Pharmacogenomic testing in psychiatry is an emerging area with potential clinical application of guiding medication choice and dosing. Interest has been fanned by commercial pharmacogenomic providers who have commonly marketed combinatorial panels that are direct-to-consumer. However, this has not been adopted widely due to a combination of barriers that include a varying evidence base, clinician and patient familiarity and acceptance, uncertainty about cost-effectiveness, and regulatory requirements.
View Article and Find Full Text PDFIdentification and validation of Novel Estrogen Biosynthesis Biomarkers in Sinonasal Inverted Papilloma.
Int J Med Sci
January 2025
Department of Otolaryngology, Head and Neck Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.
Article Synopsis
- Sinonasal inverted papilloma (SNIP) has a high recurrence rate and the potential to become malignant, but its specific metabolic pathways and biomarkers are not fully understood.
- RNA sequencing identified significant gene alterations related to the estrogen biosynthesis pathway and highlighted five key biomarkers (AKR1B10, CYP1B1, CYP2C19, CYP3A5, and HSD17B13) that were correlated with SNIP pathogenesis.
- Functional analysis indicated that these biomarkers are involved in epithelial cell proliferation and EGFR signaling regulation, suggesting their potential as diagnostic and therapeutic targets for managing SNIP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!